Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: A pilot study

Journal of Cancer Research and Clinical Oncology

Volumn 128, Issue 9, 2002, Pages 484-492

  Van Zanten Przybysz, Iwona ^a   Molthoff, Carla ^a   Gebbinck, Jacqueline ^a   Von Mensdorff Pouilly, Silvia ^a   Verstraeten, Rob ^a   Kenemans, Peter ^a   Verheijen, René ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

ADCC; Chimeric MOv18; Immunotherapy; Ovarian cancer

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CHIMERIC ANTIBODY; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MOV18; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BLOOD CELL; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CELL FRACTIONATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MITOGENESIS; MONONUCLEAR CELL; OVARY CARCINOMA; PHENOTYPE; PILOT STUDY; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CD4-CD8 RATIO; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNOPHENOTYPING; INJECTIONS, INTRAVENOUS; LYMPHOCYTE ACTIVATION; MIDDLE AGED; OVARIAN NEOPLASMS; PILOT PROJECTS; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME;

EID: 0036380518     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-002-0348-z     Document Type: Article

References (51)

1. Abdulhay G, DiSaia PJ, Blessing JA, Creasnan WT (1985) Human lymphoblastoid interferon in the treatment of advanced epithelial ovarian malignancies: a GOG study. Am J Obstetr Gynecol 152:418-423
2. Albertini MR, Hank JA, Schiller JH, Khorsand M, Borchert AA, Gan J, Bechhofer R, Store B, Reisfeld RA, Sondel PM (1997) Phase IB trial of chimeric antisialoganglioside antibody plus interleukine-2 for melanoma patients. Clin Cancer Res 3:1277-1288
3. Baker TS, Bose CC, Caskey-Finney HM, King DJ, Lawson AD, Lyons A, Mountain A, Owens RJ, Rolfe MR, Sehdev M (1994) Humanization of an anti-mucin antibody for breast and ovarian cancer therapy. Adv Exp Med Biol 353:61-82
4. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L (1996) Phase II study of weekly intravenous recombinant humanized anti-p185 (her2) monoclonal antibody in patients with her2/neu- overexpressing metastatic breast cancer. J Clin Oncol 14:737-744
5. Baum RP, Noujaim AA, Nanci A, Moebus V, Hertel A, Niesen A (1993) Clinical course of ovarian cancer patients under repeated stimulation of HAMA using MAb-OC 125 and B43.13. Hybridoma 12:583-589
6. Benard J, Da Silva J, De Blois M, Boyer P, Duvillard P, Chiric E (1985) Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. Cancer Res 45:4970-4979
7. Berek JS, Hacker NF, Lichtenstein A, Jung T, Spiha C, Knox RM, Brady J, Green T, Ettinger LM, Lagasse LD (1985) Intraperitoneal recombinant alpha2 interferon for salvage epithelial ovarian cancer in Stage III: a GOG study. Cancer Treat Res 12:23-32
8. Bezwoda WR, Golombick T, Dansey R, Keeping J (1991) Treatment of malignant ascites due to recurrent/refractory ovarian cancer: the use of interferon-alpha or interferon-alpha plus chemotherapy. In vivo and in vitro observations. Eur J Cancer 27:1423-1429
9. Buist MR, Kenemans P, Den Hollander W, Vermorken JB, Molthoff CF, Burger CW, Helmerhorst TJ, Baak JP, Roos JC (1993) Kinetics and tissue distribution of the radiolabeled chimeric monoclonal antibody MOv18 IgG and F(ab')2 fragments in ovarian carcinoma patients. Cancer Res 53:5413-5418
10. Buist MR, Molthoff CF, Kenemans P, Meijer CJ (1995) Distribution of OV-TL 3 and MOv18 in normal and malignant ovarian tissue. Cancer Immunol Immunother 48:631-636
11. Campbell IG, Jones TA, Foulkes WD, Trowsdale J (1991) Folate-binding protein is a marker for ovarian cancer. Cancer Res 51:5329-5338
12. Coney LR, Tomassetti A, Carayannopoulos L, Frasca V, Kamen BA, Colnaghi MI, Zurawski VR Jr (1991) Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein. Cancer Res 51:6125-6132
13. Coney LR, Mezzanzanica D, Sanborn D, Casalini P, Colnaghi MI, Zurawski VR Jr (1994) Chimeric murine-human antibodies directed against folate binding receptor are efficient mediators of ovarian carcinoma cell killing. Cancer Res 54:2448-2455
14. Crippa F, Buraggi GL, Di Re E, Gasparini M, Seregni E, Canevari S, Gadina M, Presti M, Marini A (1991) Radioimmunoscintigraphy of ovarian cancer with the MOv18 monoclonal antibody. Eur J Cancer 27:724-729
15. Crippa F, Bolis G, Seregni E, Gavoni N, Scarfone G, Ferraris C, Buraggi GL, Bombardieri E (1995) Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody I-131 MOv18: clinical results in patients with minimal residual disease of ovarian cancer. Eur J Cancer 31A:686-690
16. Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, LoBuglio AF, Jonas C, Klippenstein D, Dallaire B, Varus C (1999) Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17:268-276
17. Dilmann RO (1994) Antibodies as cytotoxic therapy. J Clin Oncol 12:1497-1515
18. Edwards RP, Gooding W, Lembersky BC, Colonello K, Hammond R, Paradise C, Kowal CD, Kuschner AJ, Baldisseri M, Kirkwood JM, Herberman RB (1997) Comparison of toxicity and survival following intraperitoneal recombinat interleukin-2 for persistent ovarian after platinum: twenty-four-hour versus 7-day infusion. J Clin Oncol 15:3399-3407
19. Elsasser-Beile U, Von Kleist S, Sauther W, Gallati H, Schulte Monting J (1993) Impaired cytokine production in whole blood cell cultures of patients with gynaecological carcinomas in different clinical stages. Brit J Cancer 68:32-36
20. Elwood PC, Kane MA, Portillo RM, Kolhouse JF (1986) The isolation, characterization and comparison of the membrane associated and soluble folate-binding proteins for human KB cells. J Biol Chem 261:15625-15631
21. Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S, Tedesco F, Rambaldi A, Introna M (2000) Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 95:3900-3908
22. Goodman GE, Hellstrom I, Brodzinsky L, Nicaise C, Kulander B, Hummel D (1990) Phase I trial of murine monoclonal antibody L6 in breast, colon, ovarian, and lung cancer. J Clin Oncol 8:1083-1092
23. Greiner JW, Guadagni F, Goldstein D, Smalley RV, Borden EC, Simpson JF, Molinolo A, Schlom J (1992) Intraperitoneal administration of interferon-gamma to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells. J Clin Oncol 10:735-746
24. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA (1982) Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin-2-activated autologous human peripheral blood lymphocytes. J Exp Med 155:1823-1841
25. Hank JA, Surfus J, Gan J, Chew TL, Hong R, Tans K, Reisfeld R, Seeger RC, Reynolds CP, Bauer M (1994) Treatment of neuroblastoma patients with antiganglioside GD2 antibody plus interleukin-2 induces antibody-dependent cellular cytotoxicity against neuroblastoma detected in vitro. J Immunother 15:29-37
26. Hjelm AL, Skog A, Ragnhammar P, Fagerberg J, Frodin J, Goldinger M, Koldestam H, Lijefors M, Nilsson B, Shetye J, Wersall P, Mellstedt H (1999) Clinical effects of monoclonal antibody 17-1A combined with granulocyte/macrophage-colony-stimulating factor and interleukin-2 for treatment of patients with advanced colorectal carcinoma. Cancer Immunol Immunother 48:463-470
27. Khazaeli MB, Conry RM, LoBuglio AF (1994) Human immune response to monoclonal antibodies. J Immunother 15:42-52
28. Kosmas C, Epenetos AA, Courtnay-Luck NS (1994) Activation of cellular immunity after intracavitary monoclonal antibody therapy of ovarian cancer. Cancer 73:3000-3010
29. Lai CH, Rabinowitch H, Crowley-Nowick PA, Bell MC, Mantovani G, Whiteside TL (1996) Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma. Clin Cancer Res 2:161-173
30. Ligtenberg MJ, Vos HL, Hilkens J (1990) Episialin, a carcinoma-associated mucin, is generated by a polymorphic gene encoding slice variants with alternative amino termini. J Biol Chem 265:5573-5578
31. Markman M, Berek JS, Blessing JA, McGuire WP, Bell J, Homeseley HD (1992) Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based ip chemotherapy: lessons learned from a GOG phase II trial of ip cisplatin and recombinant alpha-interferon. Gynecol Oncol 45:3-8
32. Marth C, Zeimet AG, Bock G, Daxenbichler G (1998) Modulation of tumour marker CA-125 expression in cultured ovarian carcinoma cells. Eur J Cancer 28A:2002-2006
33. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833
34. Miotti S, Canevari S, Menard S, Mezzanzanica D, Porro G, Pupa SM, Regazzoni M, Tagliabue E, Colnaghi MI (1987) Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int J Cancer 39:297-303
35. Molthoff CFM, Buist MR, Kenemans P, Pinedo HM, Boven E (1992) Experimental and clinical analysis of the characteristics of a chimeric monoclonal antibody, MOv18, reactive with an ovarian cancer-associated antigen. J Nucl Med 33:2000-2005
36. Molthoff CF, Prinssen HM, Kenemans P, Van Hof AC, Den Hollander W, Verheijen RH (1997) Escalating protein doses of chimeric monoclonal antibody MOv18 immunoglobulin G in ovarian carcinoma patients: a phase I study. Cancer 8:2712-2720
37. Nardi M, Cognetti F, Pollera CF, Giulia MD, Lombardi A, Atlante G, Calabresi F (1990) Intraperitoneal alpha-2-interferon alternating with cisplatin as salvage therapy for minimal residual disease ovarian cancer: a phase II study. J Clin Oncol 6:1036-1041
38. Niloff JM, Knapp RC, Jones G, Schaetzl ME, Bast RC Jr (1985) Recombinant leukocyte alpha interferon in advanced ovarian carcinoma. Cancer Treat Rep 69:895-896
39. Pellegrini P, Berghella AM, Del Beato T, Cicia S, Adorno D, Casciani CU (1996) Disregulation in TH1 and TH2 subsets of CD4+ T cells in peripheral blood colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol Immunother 42:01-08
40. Pross HF, Lotzova E (1993) Role of natural killer cells in cancer. Nat Immun 12:279-292
41. Pujade-Lauraine E, Guastella JP, Colombo N, Devillier P, Francois E, Fumoleau P, Monnier A, Nooy M, Mignot L, Bugat R, Marques C, Mousseau M, Netter G, Maloisel F, Larbaoui S, Brandely M (1996) Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. J Clin Oncol 14:343-350
42. Rabinowitch H, Suminami Y, Reichert DE, Crowley-Nowick PA, Bell MC, Edwards R (1996) Expression of cytokine genes or proteins and signaling molecules on lymphocytes associated with human ovarian cancer. Int J Cancer 68:276-284
43. Riethmuller G, Schlimok G, Schmiegel W, Raab R, Hoffen K, Gruber R, Funke I, Pilchmaier H, Hirche H, Buggisch P, Witte J, Pilchmayr R (1998) Monoclonal antibody therapy for resected Duke's C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncology 16:1788-1794
44. Safa MM, Foon KA (2001) Adjuvant immunotherapy for melanoma and colorectal cancers. Semin Oncol 28:68-92
45. Schroder W, Vering A, Stegmuller M, Strohmeier R (1997) Lymphocyte subsets in patients with ovarian and breast cancer. Eur J Gyn Oncol 18:474-477
46. Shinegori G, Manami S, Ryuka K, Masayoshi I, Shinobu S, Shouman T (1999) Analysis of TH1 and TH2 cytokine production by peripheral blood mononuclear cells as a parameter of immunological dysfunction in advanced cancer patients. Cancer Immunol Immunother 48:435-431
47. Steplewski Z, Sun LK, Sherman CW, Ghrayeb J, Daddona P, Koprowski H (1988) Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity. Proc Natl Acad Sci USA 85:4852-4856
48. Tong AW, Seamour B, Lawson JM, Ordonez G, Vukelja S, Hyman W, Richards D, Stein L, Maples PB, Nemunaitis J (2000) Cellular immune profile of patients with advanced cancer before and after taxane treatment. Am J Clin Oncol 23:463-472
49. Trimble EL, Adams JD, Vena D, Hawkins MJ, Friedman MA, Fisherman JS, Christian MC, Canetta R, Onetto N, Hayn R (1993) Paclitaxel for platinum-refractory ovarian cancer-results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 11:2405-2410
50. Venesmaa AA (1994) Epithelial ovarian cancer: impact of surgery and chemotherapy on survival during 1977-1990. Obstet Gynecol 84:01-08
51. Willemse PHB, De Vries EGE, Mulder NH, Aalders JG, Bouma J, Sleijter DT (1990) Intraperitoneal human recombinant interferon alpha-2b in minimal residual ovarian cancer. Eur J Cancer 26:353-358